EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Serum Copeptin Rises After Tolvaptan for Hyponatraemia, but Does Not Predict Risk of Rapid Sodium Rise: Pre‐Specified Secondary Analysis of the TVFR Trial

Annabelle M Warren iD, Kay Weng Choy, Rudolf Hoermann, Nicholas Russell, Mathis Grossmann iD

Clinical Endocrinology · 2026

DOI: 10.1111/cen.70184 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Endocrinology, 2026. Verfasst von Annabelle M Warren und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Austin Health, Heidelberg, Victoria, Australia. Hauptthemen laut MEDLINE: Tolvaptan, Hyponatremia, Glycopeptides, Sodium. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, Endocrine Society of Australia, Otsuka Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Hyponatraemia is a common electrolyte disorder often driven by excess arginine vasopressin (AVP). Copeptin is a stable surrogate marker co‐secreted with AVP. It is unclear whether treatment of hyponatraemia with tolvaptan, an AVP‐V2 receptor antagonist, impacts copeptin. We aimed to assess the effects of tolvaptan on serum copeptin, compared to fluid restriction.

Design

Pre‐specified secondary analysis of an open‐label randomised trial comparing tolvaptan or fluid restriction for 3 days. Patients Hospitalised patients with plasma sodium (pNa) 115–130 mmol/L at a single‐centre tertiary hospital in Melbourne, Australia.

Measurements

Copeptin measured at baseline and completion (Day 4, or discharge if sooner).

Results

Copeptin results were available in 45/54 participants, randomised to tolvaptan ( n = 25) or FR ( n = 20). Mean baseline copeptin was 10.4 pmol/L. pNa increased in both groups, significantly more with tolvaptan as previously reported. Copeptin remained stable after FR, but significantly increased after tolvaptan (mean adjusted difference between groups over 3 days 8.4 pmol/L, 95% CI 2.1–14.6, p = 0.01). Baseline copeptin did not predict rapid sodium rise. The rise in copeptin after tolvaptan may represent an exaggerated response to osmolality rise in these patients (‘reset osmostat’), or feedback mechanisms from AVP blockade.

Conclusion

Tolvaptan increased serum copeptin compared to fluid restriction. Further research is required to determine if there is clinical utility for measuring copeptin in hyponatraemia before it is adopted into practice. Trial Registration: ACTRN12619001683123.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TolvaptanHyponatremiaGlycopeptidesSodiumAntidiuretic Hormone Receptor AntagonistsHumansFemaleMaleMiddle AgedAgedArginine VasopressinBenzazepines

Stichwörter der Autor:innen

arginine vasopressin (AVP)copeptinhyponatremia (hyponatraemia)syndrome of inappropriate antidiuresis (SIAD, SIADH)tolvaptan

Substanzen

TolvaptancopeptinsGlycopeptidesSodiumAntidiuretic Hormone Receptor AntagonistsArginine VasopressinBenzazepines

Autor:innen und Institutionen

  • Department of Endocrinology, Austin Health, Heidelberg, Victoria, Australia.
  • Department of Medicine, Austin Health, University of Melbourne, Heidelberg, Victoria, Australia.
  • Department of Endocrinology and Diabetes, Alfred Health, Melbourne, Victoria, Australia.
  • Northern Pathology Victoria, Northern Health, Epping, Victoria, Australia.

ORCID-Profile: Annabelle M Warren, Mathis Grossmann

Förderung

  • National Health and Medical Research Council
  • Endocrine Society of Australia
  • Otsuka Pharmaceutical

Zitieren

APA

Warren, A. M., Choy, K. W., Hoermann, R., Russell, N., & Grossmann, M. (2026). Serum Copeptin Rises After Tolvaptan for Hyponatraemia, but Does Not Predict Risk of Rapid Sodium Rise: Pre‐Specified Secondary Analysis of the TVFR Trial. Clinical Endocrinology. https://doi.org/10.1111/cen.70184

Vancouver

Warren AM, Choy KW, Hoermann R, Russell N, Grossmann M. Serum Copeptin Rises After Tolvaptan for Hyponatraemia, but Does Not Predict Risk of Rapid Sodium Rise: Pre‐Specified Secondary Analysis of the TVFR Trial. Clinical Endocrinology. 2026. doi:10.1111/cen.70184

BibTeX
@article{Warren2026,
  author = {Warren, Annabelle M and Choy, Kay Weng and Hoermann, Rudolf and Russell, Nicholas and Grossmann, Mathis},
  title = {Serum Copeptin Rises After Tolvaptan for Hyponatraemia, but Does Not Predict Risk of Rapid Sodium Rise: Pre‐Specified Secondary Analysis of the TVFR Trial},
  journal = {Clinical Endocrinology},
  year = {2026},
  doi = {10.1111/cen.70184}
}
Kostenlos starten →